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Abstract 
The impact of donor lymphocyte infusion (DLI) initial cell dose on its outcome is known in patients 
with chronic myeloid leukemia but limited in patients with other hematological malignancies. In 
this retrospective study, we evaluated the effect of initial DLI CD3
+
 cell dose on graft-versus-host 
disease (GVHD) and overall survival after DLI given for relapse of any hematological malignancies 
after allogeneic hematopoietic cell transplantation (HCT) with high- or reduced-intensity 
conditioning. The cohort included 225 patients. Initial DLI CD3
+
 cell dose per kilogram of recipient 
body weight was ≤1 × 107 (n = 84; group A), >1.0 to <10 × 107 (n = 58; group B), and ≥10 × 107 
(n = 66; group C). The initial cell dose was unknown for the remaining 17 patients. Cumulative 
incidence rates of GVHD at 12 months after DLI were 21%, 45%, and 55% for groups A, B, and C, 
respectively. Multivariate analysis showed that initial DLI CD3
+
 cell ≥10 × 107 dose per kilogram is 
associated with an increased risk of GVHD after DLI (P = .03). Moreover, an initial DLI CD3
+
 cell 
dose of 10 × 10
7
 or higher did not decrease the risk of relapse and did not improve overall survival. 
Thus, these results support the use of less than 10 × 10
7
 CD3
+
 cell per kilogram as the initial cell 
dose of DLI for treatment of persistent or recurrent hematological malignancy after HCT. 
 
Introduction 
 
Allogeneic hematopoietic cell transplantation (HCT) has the potential to provide long-term survival 
and even cure in patients with hematological malignancies 1 and 2. Nonetheless, relapse of 
malignancy after HCT remains a major cause of transplantation failure. Donor lymphocyte infusion 
(DLI) is one approach frequently used to treat patients with relapse of hematologic malignancy after 
allogeneic HCT. The DLI effect is mediated through the immunologic antitumor activity of donor T 
cells and possibly natural killer cells 3, 4, 5 and 6. Since the first report of DLI in patients with 
relapsed chronic myeloid leukemia (CML) after allogeneic HCT by Kolb et al. in 1990 [6], DLI has 
become a common approach to treat not only CML but also acute leukemia, lymphoma, 
myelodysplastic syndrome (MDS), and multiple myeloma (MM) that have relapsed after allogeneic 
HCT 7, 8, 9, 10, 11, 12 and 13. The beneficial graft-versus-leukemia effect of DLI may be offset by 
morbidity and mortality related to graft-versus-host disease (GVHD). Although a low initial cell 
dose followed by escalation of doses of DLI can minimize the risk of GVHD in patients treated for 
relapsed CML 14, 15 and 16, the data regarding the impact of initial cell dose on outcomes after 
DLI for other relapsed hematological malignancies are limited. The primary objective of the current 
study was to determine the effect of the initial DLI CD3
+
 T cell dose on subsequent GVHD 
requiring systemic treatment and on overall survival (OS) after DLI. 
 
Patients and Methods 
 
The study cohort included 225 patients treated with DLI for relapsed hematological malignancies 
after allogeneic HCT from November 1993 through October 2011. Patients received high- or 
reduced-intensity conditioning regimens before HCT according to standard treatment plan or 
prospective clinical trials and were treated at the Fred Hutchinson Cancer Research Center (n = 
212) and at 3 participant institutions in the Seattle Nonmyeloablative HCT Consortium: the 
University of Torino (n = 9), the Puget Sound VA Health Care System (n = 2), and the Medical 
College of Wisconsin (n = 2). Follow-up was complete through July 2012. All patients provided 
informed consent for treatment according to transplantation protocols approved by each institutional 
review board. In addition, separate institutional approval was obtained to gather data from patient 
records and databases retrospectively. 
 
DLI 
 
All 225 patients in this study received DLI for treatment of relapsed hematological malignancies 
after HCT. No prophylactic DLI treatment was given. One hundred fifty-four patients were treated 
with DLI in prospective clinical trials, and 71 patients received DLI as a treatment plan. Patients 
with rapidly progressive malignancies (ie, acute myeloid or lymphoid leukemia, CML in blast 
phase, high-grade MDS, intermediate-high grade non-Hodgkin lymphoma, Hodgkin lymphoma, or 
aggressive multiple myeloma) received chemotherapy or radiation before DLI according to specific 
protocols or at the discretion of the attending physician. Treatment with tyrosine kinase inhibitor or 
interferon was generally discontinued before DLI. Patients were eligible to receive DLI if they were 
not receiving systemic treatment for GVHD, had no evidence of active GVHD at the time of DLI, 
and had evidence of donor chimerism. No immunosuppressive agents were given after DLI to 
prevent GVHD. Among 128 patients with available information regarding the DLI product, 32 
patients received a granulocyte-colony stimulating factor (G-CSF) mobilized product for DLI. 
Twelve patients received IL-2 after DLI as part of a prospective clinical trial, as previously 
described [17]. 
 
GVHD Definition 
 
DLI-related GVHD was defined as any acute GVHD [18] or chronic GVHD (NIH criteria or 
historical criteria) 19 and 20 after DLI that required systemic treatment. As clinically acute and 
chronic GVHD occurring after DLI have overlapping onset times 21 and 22, for the purpose of 
evaluating the incidence of GVHD after DLI, we defined DLI-related GVHD as any GVHD after 
DLI (acute or chronic) that required systemic treatment. Serious GVHD after DLI was evaluated 
according to previously reported criteria [23]. 
 
Statistical Methods 
 
Overall survival after DLI was estimated by the Kaplan-Meier method. Cumulative incidence of 
relapse and GVHD after DLI were estimated by standard methods, treating death as a competing 
risk. Cox regression was used to evaluate risk factors for GVHD, OS, and relapse and disease 
progression after DLI. Risk factors evaluated in univariate analysis for each of the outcomes 
(GVHD, OS, and relapse or disease progression after DLI) included initial DLI CD3
+
 cell dose, 
patient age at DLI, donor-recipient gender, diagnosis at time of DLI, disease status at time of DLI, 
donor origin, donor-recipient HLA match, graft stem cell source, conditioning intensity, acute and 
chronic GVHD before DLI, interval between HCT to DLI, cytoreductive treatment before DLI, 
donor blood CD3 and whole marrow chimerism at the time of DLI, lymphocyte count at the time of 
DLI, use of G-CSF-mobilized product for DLI, use of IL-2 after DLI, and year of DLI. Multivariate 
models included all factors significant at the .05 level in univariate analysis for each outcome, as 
well as age and the factors most significantly disparate among the cell dose groups (donor origin, 
conditioning intensity, and year of DLI). In analyzing the impact of subsequent DLI on overall 
survival, the second DLI was treated as a time-dependent covariate in a Cox regression model. 
Comparisons of CD3
+
 cell dose between the initial and second DLI was by paired t-test. 
 
Results 
 
Patient Characteristics 
A total of 225 patients underwent treatment with DLI for persistent or relapse hematological 
malignancies after HCT including CML (n = 56), acute myeloid leukemia (AML) (n = 71), MDS 
(n = 22), acute lymphoblastic leukemia (ALL) (n = 21), MM (n = 23), lymphoma (n = 21), chronic 
lymphocytic leukemia (CLL)/lymphoma (n = 8), myelofibrosis (n = 2), and myeloproliferative 
disorder (n = 1). Patients were classified into one of the following risk categories: (1) high-risk 
myeloid malignancies group that included patients with AML, MDS, CML (blast crisis [BC], 
accelerated phase [AP]), myelofibrosis, and myeloproliferative disorder, (n = 111); (2) high-risk 
lymphoid malignancies group that included patients with ALL and high-grade lymphomas 
(Hodgkin lymphoma, diffuse large B cell lymphoma, transformed non-Hodgkin lymphoma), (n = 
37); (3) low-risk lymphoid malignancies group that included patients with CLL, MM, other 
lymphomas, (n = 36); and (4) those with CML-chronic phase (CP) (n = 41). 
The median age of the 225 patient cohort was 46 years (range, 3 to 74), and 59% (n = 132) were 
male. Patients received transplantations from HLA-matched related (n = 171) or unrelated (n = 41) 
donors. Thirteen patients had HLA-mismatched donors, and 58 patients (26%) received reduced-
intensity conditioning regimens before HCT. The median time interval from HCT to relapse was 
11.3 months (range, 1 to 180); from HCT to DLI, 15.5 months (range, 21.1 to 215). One hundred 
forty-four patients (64%) received cytoreductive therapy before DLI, and 55 patients (24%) had 
achieved complete remission at the time of DLI. The initial DLI CD3
+
 cell dose per kilogram was 
≤1 × 107 in 84 patients (group A), >1.0 to <10 × 107 in 58 patients (group B), and ≥10 × 107 in 66 
patients (group C). The remaining 17 patients received an unknown initial dose. Median follow-up 
after DLI was 78 months (range, .1 to 197). Characteristics of the cohort according to the initial DLI 
CD3
+
 cell dose administered are shown in Table 1. 
Table 1.  
Patient Characteristics 
Characteristic 
CD3
+
 Cell Dose, per Kilogram 
 
Unknown 
(n = 17) 
Group A 
≤107 (n = 
84) 
Group B 
>10
7
 to <10
8
 
(n = 58) 
Group C 
≥108 (n = 
66) 
P Value 
∗
 
Patient age at DLI     .14 
 0-29 yr 4 12 (14) 13 (22) 9 (14)  
 30-44 yr 7 25 (30) 11 (19) 27 (41)  
 45-59 yr 5 29 (35) 25 (43) 22 (33)  
 60-74 yr 1 18 (21) 9 (16) 8 (12)  
Donor-recipient gender (n = 
220) 
    .17 
 Other 14 65 (82) 40 (69) 52 (79)  
 Female to male 3 14 (18) 18 (31) 14 (21)  
Disease diagnosis/risk at time 
of DLI 
    .36 
 CML–chronic phase 6 16 (19) 9 (16) 10 (15)  
 Low-risk lymphoid 
malignancies
†
 
0 20 (24) 6 (10) 10 (15)  
 High-risk myeloid 
malignancies
‡
 
6 36 (43) 32 (55) 37 (56)  
 High-risk lymphoid 
malignancies
§
 
5 12 (14) 11 (19) 9 (14)  
Characteristic 
CD3
+
 Cell Dose, per Kilogram 
 
Unknown 
(n = 17) 
Group A 
≤107 (n = 
84) 
Group B 
>10
7
 to <10
8
 
(n = 58) 
Group C 
≥108 (n = 
66) 
P Value 
∗
 
Disease status at time of DLI     .05 
 Complete remission 2 14 (17) 19 (33) 20 (30)  
 Not in complete remission 15 70 (83) 39 (67) 46 (70)  
Donor origin     <.0001 
 Related 13 48 (57) 46 (79) 64 (97)  
 Unrelated 4 36 (43) 12 (21) 2 (3)  
Donor-recipient HLA match     .07 
 Matched 13 77 (92) 57 (98) 65 (98)  
 Mismatched 4 7 (8) 1 (2) 1 (2)  
Graft stem cell source (n = 201)     .004 
 Bone marrow 12 31 (49) 21 (38) 45 (68)  
 Mobilized blood 5 32 (51) 34 (62) 21 (32)  
Conditioning intensity     <.0001 
 Myeloablative 16 47 (56) 41 (71) 63 (95)  
 Nonmyeloablative 1 37 (44) 17 (29) 3 (5)  
Prior acute GVHD (n = 218)     .05 
 0-I 4 34 (44) 25 (43) 17 (26)  
 II-IV 13 43 (56) 33 (57) 49 (74)  
Prior chronic GVHD     .14 
 No 11 60 (71) 39 (67) 37 (56)  
 Yes 6 24 (29) 19 (33) 29 (44)  
Time from HCT to DLI     .50 
 >1 yr 11 51 (61) 31 (53) 42 (64)  
 ≤1 yr 6 33 (39) 27 (47) 24 (36)  
Cytoreduction before DLI (n = 
220) 
    .02 
 No 6 37 (45) 18 (31) 15 (24)  
 Yes 11 45 (55) 40 (69) 48 (76)  
Donor CD3 chimerism at time 
of DLI (n = 91) 
    .70 
 >95% 1 32 (70) 20 (71) 7 (58)  
 ≤95% 4 14 (30) 8 (29) 5 (42)  
Donor BM chimerism at time of 
DLI (n = 114) 
    .75 
 >95% 5 25 (54) 18 (60) 13 (50)  
 ≤95% 7 21 (46) 12 (40) 13 (50)  
Lymphocyte count at time of 
DLI (n = 217) 
    .01 
Characteristic 
CD3
+
 Cell Dose, per Kilogram 
 
Unknown 
(n = 17) 
Group A 
≤107 (n = 
84) 
Group B 
>10
7
 to <10
8
 
(n = 58) 
Group C 
≥108 (n = 
66) 
P Value 
∗
 
 ≥103/μL 10 47 (61) 24 (42) 25 (38)  
 <10
3/μL 7 30 (39) 33 (58) 41 (62)  
G-CSF mobilized product for 
DLI (n = 128) 
    .02 
 No 0 41 (84) 37 (79) 18 (56)  
 Yes 0 8 (16) 10 (21) 14 (44)  
IL-2 after DLI     .02 
 No 15 83 (99) 55 (95) 58 (88)  
 Yes 2 1 (1) 3 (5) 8 (12)  
Year of DLI     <.0001 
 1992-1996 6 5 (6) 8 (14) 23 (35)  
 1997-2001 6 26 (31) 14 (24) 33 (50)  
 2002-2006 2 30 (36) 27 (47) 10 (15)  
 2007-2011 3 23 (27) 9 (16) 0  
 
DLI indicates donor lymphocyte infusion; CML, chronic myeloid leukemia; GVHD, grant-versus-
host disease; HCT, hematopoietic cell transplantation; BM, bone marrow; G-CSF, granulocyte-
colony stimulating factor. 
Data are presented as n (%) unless otherwise indicated. 
∗ 
Among groups A, B, and C. 
† 
Includes chronic lymphocytic leukemia/lymphoma, multiple myeloma, lymphomas not high grade. 
‡ 
Includes acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia (blast 
crisis, accelerated phase), myelofibrosis, myeloproliferative disorders. 
§ 
Includes acute lymphoblastic leukemia, high-grade lymphomas (Hodgkin lymphoma, diffuse large 
B cell lymphoma, transformed non-Hodgkin lymphoma). 
 
 
GVHD after DLI 
Of the 225 treated patients, 86 (39%) developed GVHD that required systemic therapy after DLI, 
and 29 of 86 cases had serious GVHD as previously defined [23]. The median interval from DLI to 
GVHD that required systemic treatment was 39 days (range, 6 to 1029). The incidence rates of 
GVHD at 12 months after DLI according to initial cell dose were 21%, 45%, and 55% for groups A, 
B, and C, respectively (Figure 1A). 
 
Figure 1.  
Outcome after donor lymphocyte infusion (DLI) according to initial DLI cell dose. (A) Shows 
cumulative incidence of graft-versus-host disease after DLI according to initial CD3
+
 cell dose. 
Twelve-month cumulative incidence of GVHD for initial DLI cell dose group A (≤1 × 107 CD3+ 
cell/kg) was 21%, compared with 45% (P = .01) for initial cell dose group B (>1 × 10
7
 to <10 × 10
7
 
CD3
+
 cell/kg) and 55% (P < .0001) for initial cell dose group C (≥10 × 107 CD3+ cell/kg). (B) 
Shows overall survival after DLI according to initial CD3
+
 cell dose. Three-year overall survival 
rates were 47% for cell dose group A, 45% (P = .16) for cell dose group B, and 32% for cell dose 
group C (P = .01). 
 
Results of univariate and multivariate analysis of risk factors for the development of GVHD after 
DLI are shown in Table 2. In the multivariate analysis, 2 factors showed a statistically significant 
association with increased risk of GVHD after DLI: (1) initial DLI CD3
+
 cell dose ≥10 × 107/kg 
(hazard ratio [HR], 2.4; 95% CI, 1.1 to 5.4; P = .03), and (2) short interval between transplantation 
to DLI of 1 year or less (HR, 2.95; 95% CI, 1.7 to 5.2; P = .0002) ( Table 2). In univariate analysis, 
higher initial CD3
+
 cell dose was associated with an increased risk for serious GVHD after DLI for 
group B (HR, 4.34; 95% CI, 1.4 to 13.6; P = .01) and for group C (HR, 4.80; 95% CI, 1.6 to 14.7; 
P = .006) compared to group A. Because of the small number of patients experiencing serious 
GVHD, multivariate analysis was not performed. Although DLI given in more recent years was 
associated with a decreased risk of GVHD in the univariate analysis, this factor did not reach 
statistical significance in the multivariate analysis. A history of acute or chronic GVHD before DLI 
or donor type was not statistically significantly associated with increased risk of GVHD after DLI ( 
Table 2). 
Table 2.  
Risk Factors Analysis for GVHD after DLI 
 
Univariate 
 
Multivariate (n = 194) 
 
HR (95% CI) P Value HR (95% CI) P Value 
CD3
+
 cell dose     
 ≤107 cells/kg 1.0  1.0  
 >10
7
 to <10
8
 cells/kg 2.74 (1.5-5.0) .001 1.82 (.9-3.7) .10 
 ≥108 cells/kg 3.87 (2.2-6.9) <.0001 2.40 (1.1-5.4) .03 
Patient age at DLI     
 0-29 yr 1.0  1.0  
 30-44 yr 1.06 (.6-2.0) .86 .82 (.4-1.8) .62 
 45-59 yr 1.26 (.7-2.3) .46 1.35 (.6-2.8) .42 
 60-74 yr .45 (.2-1.1) .09 .55 (.2-1.8) .32 
Donor-recipient gender     
 Other 1.0    
 Female to male 1.26 (.8-2.1) .37   
Disease diagnosis/risk at time of DLI     
 CML-chronic phase 1.0  1.0  
 Low-risk lymphoid malignancies
∗
 .94 (.4-2.3) .89 1.04 (.3-3.8) .95 
 High-risk myeloid malignancies
†
 2.53 (1.3-4.8) .005 1.72 (.6-4.8) .30 
 High-risk lymphoid malignancies
‡
 1.65 (.7-3.7) .23 1.41 (.4-4.7) .58 
Disease status at time of DLI     
 Complete remission 1.0  1.0  
 Not in complete remission .61 (.4-1.0) .03 .99 (.5-1.8) .97 
Donor origin     
 Related 1.0  1.0  
 Unrelated .76 (.5-1.3) .29 .99 (.5-2.0) .97 
Donor-recipient HLA match     
 Matched 1.0    
 Mismatched 1.10 (.4-2.7) .84   
Graft stem cell source     
 Bone marrow 1.0    
 Mobilized blood 1.04 (.7-1.6) .86   
Conditioning intensity     
 Myeloablative 1.0  1.0  
 Nonmyeloablative .57 (.3-1.0) .04 .71 (.3-1.6) .42 
Prior acute GVHD (n = 218)     
 0-I 1.0    
 II-IV 1.32 (.8-2.1) .23   
Prior chronic GVHD     
 No 1.0    
 Univariate 
 
Multivariate (n = 194) 
 
HR (95% CI) P Value HR (95% CI) P Value 
 Yes 1.24 (.8-1.9) .34   
Time from HCT to DLI     
 >1 yr 1.0  1.0  
 ≤1 yr 2.57 (1.7-3.9) <.0001 2.95 (1.7-5.2) .0002 
Cytoreduction before DLI     
 No 1.0  1.0  
 Yes 1.88 (1.2-3.1) .01 1.32 (.6-2.9) .48 
Donor CD3 chimerism at time of DLI     
 >95% 1.0    
 ≤95% 1.87 (.8-4.1) .12   
Donor BM chimerism at time of DLI     
 >95% 1.0    
 ≤95% 1.26 (.7-2.3) .46   
Lymphocyte count at time of DLI     
 ≥103/μL 1.0  1.0  
 <10
3/μL 2.13 (1.4-3.3) .0008 1.41 (.8-2.3) .19 
G-CSF mobilized product for DLI     
 No 1.0    
 Yes .95 (.5-1.8) .87   
IL-2 after DLI     
 No 1.0    
 Yes 1.22 (.6-2.6) .62   
Year of DLI     
 1992-1996 1.0  1.0  
 1997-2001 .77 (.4-1.3) .34 .93 (.5-1.8) .83 
 2002-2006 .57 (.3-1.0) .05 .67 (.3-1.3) .25 
 2007-2011 .21 (.1-.6) .002 .33 (.1-1.1) .07 
DLI indicates donor lymphocyte infusion; HR, hazard ratio; CML, chronic myeloid leukemia; 
GVHD, grant-versus-host disease; HCT, hematopoietic cell transplantation; BM, bone marrow; G-
CSF, granulocyte-colony stimulating factor. 
∗ 
Includes chronic lymphocytic leukemia/lymphoma, multiple myeloma, lymphomas not high grade. 
† 
Includes acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia (blast 
crisis, accelerated phase), myelofibrosis, myeloproliferative disorders. 
‡ 
Includes acute lymphoblastic leukemia, high-grade lymphomas (Hodgkin lymphoma, diffuse large 
B cell lymphoma, transformed non-Hodgkin lymphoma). 
 
 
 
Overall Survival after DLI 
 
The overall survival rates at 3 years according to initial DLI cell dose were 47%, 45%, and 32% for 
groups A, B, and C, respectively (Figure 1B). At the time of analysis, 71 patients (31%) were alive 
after DLI. Survivors were 28 of 41 patients (68%) treated for CML-CP, 3 of 15 patients (20%) 
treated for CML-AP/BC, 15 of 71 patients (21%) for AML, 4 of 21 patients (19%) for ALL, 1 of 22 
patients (4%) for MDS, 7 of 23 patients (30%) for MM, 2 of 8 patients (25%) for CLL, and 8 of 21 
patients (38%) treated for lymphomas, 2 of 2 patients with myelofibrosis, and 1 patient with 
myeloproliferative disorder. 
As demonstrated in Table 1, we found no statistically significant imbalance in the distribution of 
diagnosis risk groups between the 3 initial DLI CD3
+
 cell dose groups (P = .36). Because of the 
small number of patients in each of the initial DLI cell dose groups in the different diagnostic risk 
groups (ie, CML-CP, low-risk lymphoid, low-risk myeloid, and high-risk lymphoid malignancies), 
these 4 diagnostic risk groups were combined into 2 risk categories for the analysis of OS according 
to the initial DLI CD3
+
 cell dose, as follows: (1) low-risk disease, including CML-CP, CLL, MM, 
low-grade lymphomas and (2) high-risk disease, including myeloid malignancies (AML, MDS, 
CML-AP/BC), myelofibrosis, myeloproliferative disorder, and high-risk lymphoid malignancies 
(ALL, high-grade lymphomas [Hodgkin lymphoma, diffuse large B cell lymphoma, transformed 
non-Hodgkin lymphoma]). Figure 2 shows the univariate analysis of OS after DLI according to the 
initial CD3
+
 cell dose and the 2 diagnosis risk categories. The 3-year OS for the low-risk category 
was 73% for group A, 53% for group B, and 55% for group C (P = .07) ( Figure 2A). The 3-year 
OS for the high-risk category was 27% for group A, 42% for group B, and 22% for group C, but the 
difference in OS between the 3 cell doses was not statistically significant (P = .35) ( Figure 2B). 
 
Figure 2.  
Overall survival after donor lymphocyte infusion (DLI) according to initial CD3
+
 cell dose 
and disease risk category. (A) Shows the overall survival for the low-risk category. One- and 
3-year overall survival were 94% and 73% for cell dose A, 67% and 53% for cell dose B, and 
60% and 55% for cell dose C (P = .07). Low-risk category included chronic myeloid leukemia-
chronic phase and chronic lymphocytic leukemia, multiple myeloma, and low-risk 
lymphomas. (B) Shows the overall survival for the high-risk category. One- and 3-year overall 
survival were 47% and 27% for cell dose group A, 60% and 42% for cell dose group B, and 
41% and 22% for cell dose group C (P = .35). High-risk category included high-risk myeloid 
malignancies (acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia 
[blast crisis, accelerated phase], myelofibrosis, myeloproliferative disorders, and high-risk 
lymphoid malignancies [acute lymphoblastic leukemia, high-grade lymphomas [Hodgkin 
lymphoma, diffuse large B cell lymphoma, transformed non-Hodgkin lymphoma]). 
 
Univariate analysis of OS according to the initial CD3
+
 cell dose for specific diagnosis such as 
CML and other disease categories is shown in Supplemental Figure 1. For patients treated with DLI 
for relapsed CML, 3-year OS according to the initial DLI cell dose was 81% for group A, 46% for 
group B, and 50% for group C, but these differences did not reach statistical significance (P = .07) ( 
Supplemental Figure 1A). For patients given DLI for relapsed lymphoma, CLL, and MM, the 1- 
and 3-year OS were 85% and 43%, respectively, for patients given cell dose A; 91% and 64%, 
respectively for patients treated with cell dose B; and 46% and 31%, respectively, for cell dose C. 
These differences were not statistically significant (P = .25) ( Supplemental Figure 1B). No 
association between initial DLI CD3
+
 cell dose and OS was noted for patients treated for relapsed 
AML or MDS with 3-year OS of 32%, 40%, and 28% for initial DLI CD3
+
 cell doses A, B and C, 
respectively (P = .99) ( Supplemental Figure 1C). 
Results of multivariate analysis for risk factors for mortality after DLI are presented in Table 3. 
Three factors were statistically significantly associated with an increased risk of mortality after 
DLI: (1) DLI within 1 year after HCT (HR, 2.66; 95% CI, 1.7 to 4.2; P < .0001); (2) age 60 or older 
(HR, 2.69; 95% CI, 1.1 to 6.3; P = .02); and (3) high-risk lymphoid malignancies (HR, 2.62; 95% 
CI, 1.0 to 6.8; P = .05). As shown in Table 2, a trend for an association between high-risk myeloid 
malignancies and an increased mortality risk was noted (P = .06). More recent DLI was associated 
with decreased risk for mortality, with an HR of .27 (95% CI, .1 to .6; P = .002) for patients treated 
with DLI between 2007 to 2011 compared with patients treated between 1992 to 1996. Initial DLI 
cell dose did not affect mortality either for the entire cohort ( Table 3) or for the cohort of patients 
with diseases other than CML-CP (group B: HR, .88; P = .61; group C: HR, 1.22; P = .51). 
Table 3.  
Risk Factor Analysis for Overall Mortality after DLI 
 
Univariate 
 
Multivariate (n = 181) 
 
HR (95% CI) P Value HR (95% CI) P Value 
CD3
+
 cell dose     
 ≤107 cells/kg 1.0  1.0  
 >10
7
 to <10
8
 cells/kg 1.35 (.9-2.0) .16 .98 (.6-1.7) .93 
 ≥108 cells/kg 1.64 (1.1-2.4) .01 1.25 (.7-2.3) .48 
Patient age at DLI     
 0-29 yr 1.0  1.0  
 30-44 yr .99 (.6-1.6) .95 1.02 (.6-1.9) .95 
 45-59 yr 1.02 (.6-1.6) .94 1.44 (.8-2.7) .25 
 60-74 yr 1.42 (.8-2.4) .20 2.69 (1.1-6.3) .02 
 Univariate 
 
Multivariate (n = 181) 
 
HR (95% CI) P Value HR (95% CI) P Value 
Donor-recipient gender     
 Other 1.0    
 Female to male 1.19 (.8-1.7) .38   
Disease diagnosis/risk at time of DLI     
 CML-chronic phase 1.0  1.0  
 Low-risk lymphoid malignancies
∗
 2.93 (1.5-5.8) .002 1.47 (.5-4.2) .48 
 High-risk myeloid malignancies
†
 5.05 (2.8-9.1) <.0001 2.29 (1.0-5.4) .06 
 High-risk lymphoid malignancies
‡
 4.64 (2.4-9.0) <.0001 2.62 (1.0-6.8) .05 
Disease status at time of DLI     
 Complete remission 1.0    
 Not in complete remission 1.18 (.8-1.7) .39   
Donor origin     
 Related 1.0  1.0  
 Unrelated .86 (.6-1.3) .44 1.05 (.6-1.8) .87 
Donor-recipient HLA match     
 Matched 1.0    
 Mismatched 1.14 (.6-2.2) .70   
Graft stem cell source     
 Bone marrow 1.0  1.0  
 Mobilized blood 1.72 (1.2-2.4) .002 1.42 (.8-2.5) .22 
Conditioning intensity     
 Myeloablative 1.0  1.0  
 Nonmyeloablative 1.24 (.9-1.8) .24 0.75 (.4-1.6) .46 
Prior acute GVHD (n = 218)     
 0-I 1.0    
 II-IV 1.07 (.8-1.5) .68   
Prior chronic GVHD     
 No 1.0    
 Yes .98 (.7-1.4) .89   
Time from HCT to DLI     
 >1 yr 1.0  1.0  
 ≤1 yr 3.04 (2.2-4.2) <.0001 2.66 (1.7-4.2) <.0001 
Cytoreduction before DLI     
 No 1.0  1.0  
 Yes 2.35 (1.6-3.4) <.0001 1.37 (.7-2.5) .31 
Donor CD3 chimerism at time of DLI     
 >95% 1.0    
 ≤95% 1.39 (.8-2.4) .25   
Donor BM chimerism at time of DLI     
 Univariate 
 
Multivariate (n = 181) 
 
HR (95% CI) P Value HR (95% CI) P Value 
 >95% 1.0    
 ≤95% 2.08 (1.3-3.3) .003   
Lymphocyte count at time of DLI     
 ≥103/μL 1.0  1.0  
 <10
3/μL 1.72 (1.2-2.4) .001 1.16 (.8-1.8) .50 
G-CSF mobilized product for DLI     
 No 1.0    
 Yes 1.06 (.7-1.7) .81   
IL-2 after DLI     
 No 1.0    
 Yes 1.41 (.8-2.5) .23   
Year of DLI     
 1992-1996 1.0  1.0  
 1997-2001 .89 (.6-1.4) .59 .65 (.4-1.1) .10 
 2002-2006 .79 (.5-1.2) .30 .46 (.2-.9) .02 
 2007-2011 .58 (.3-1.1) .09 .27 (.1-.6) .002 
DLI indicates donor lymphocyte infusion; HR, hazard ratio; CML, chronic myeloid leukemia; 
GVHD, grant-versus-host disease; HCT, hematopoietic cell transplantation; BM, bone marrow; G-
CSF, granulocyte-colony stimulating factor. 
∗ 
Includes chronic lymphocytic leukemia/lymphoma, multiple myeloma, lymphomas not high grade. 
† 
Includes acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia (blast 
crisis, accelerated phase), myelofibrosis, myeloproliferative disorders. 
‡ 
Includes acute lymphoblastic leukemia, high-grade lymphomas (Hodgkin lymphoma, diffuse large 
B cell lymphoma, transformed non-Hodgkin lymphoma). 
 
Of the 225 patients, 46 received 2 DLIs, 13 patients received 3 DLIs, and 1 patient received 4 DLIs. 
A time-dependent Cox regression analysis showed no significant effect of subsequent DLIs on OS 
(HR, .95; 95% CI, .6 to 1.4, P = .82). 
 
Causes of Death 
 
A total of 154 patients have died. Deaths occurred in 49 of 84 patients (58%) in cell group A, in 41 
of 58 patients (71%) in cell dose group B, and in 55 of 66 patients (83%) in cell group C. The most 
common cause of death after DLI was progressive disease or relapse of malignancy in all 3 cell 
dose groups: 90% of deaths in group A, 73% of deaths in group B, and 67% of deaths in group C. 
GVHD was the primary cause of death in 4 patients (8%) in group A, 3 patients (7%) in group B, 
and 5 patients (9%) in group C. Table 4 summarizes the cause of death according to the initial DLI 
cell dose groups. 
Table 4.  
Cause of Death According to Initial DLI CD3 Cell per Kilogram Dose Groups 
 
Group A 
(n = 49) 
Group B 
(n = 41) 
Group C 
(n = 55) 
GVHD 4 (8%) 3 (7%) 5 (9%) 
Relapse or progressive disease 44 (90%) 30 (73%) 37 (67%) 
Relapse or progressive disease and GVHD 0 3 (7%) 4 (7%) 
Other cause death 0 3 (7%) 4 (7%) 
Unknown cause of death 1 (2%) 2 (5%) 5 (9%) 
GVHD indicates graft-versus-host disease. 
Data are presented as n (%) unless otherwise indicated. P = .32 (excluding unknown causes) 
 
Relapse and Disease Progression after DLI 
 
Among the 225 patients, 166 (74%) had relapse and/or progressive disease after DLI. Results of 
univariate and multivariate analysis for relapse and/or progressive disease after DLI are shown in 
Supplemental Table 1. Three factors statistically significantly affected the risk of relapse or disease 
progression after DLI in the multivariate analysis: (1) interval of 1 year or less from HCT to DLI 
(HR, 1.92; 95% CI, 1.3 to 2.9; P = .002); (2) age of 60 and older (HR, 2.33; 95% CI, 1.1 to −5.1; 
P = .03); and (3) initial CD3
+
 cell dose of >1 × 10
7
 to <10 × 10
7
/kg compared with lower cell dose 
(HR, .54; 95% CI, .3 to −.9; P = .01). Initial CD3+ cell dose of ≥10 × 107/kg was not associated 
with decreased relapse rate. Analysis for risk of relapse according to the initial DLI CD3
+
 cell dose 
among patients with diseases other than CML-CP showed similar results. The intermediate cell dose 
was associated with a decreased relapse rate (HR, .57; 95% CI, .4 to .9; P = .02), but the highest cell 
dose was not. 
 
Aplasia after DLI 
 
Aplasia after DLI was evaluated in 154 patients who participated in prospective DLI studies for 
relapsed hematological malignancies after HCT. Fifteen of 154 (9.7%) patients developed aplasia 
after DLI. Five of 15 patients received an initial DLI dose of ≥10 × 107 CD3+/kg, 2 patients 
received a dose of 9 × 10
7
 CD3
+
/kg, 1 patient received a dose of 2.5 × 10
7
 CD3
+
/kg, and the rest of 
the patients received a dose of 1 × 10
7
 CD3
+
/kg. 
 
Discussion 
 
DLI is an attractive salvage treatment option for patients with persistent or relapsed hematological 
malignancies after high- or reduced-intensity HCT 7, 8, 9, 10 and 11. Previous studies have 
suggested optimal initial total nucleated cells and lymphocyte doses of DLI associated with a low 
risk of GVHD and mortality and yet maintenance of the desirable graft-versus-malignancy effect 
for treatment of relapsed CML after allogeneic HCT 14, 15 and 16. Limited data are available on 
the impact of DLI CD3
+
 cell dose on GVHD and mortality after DLI in patients treated for other 
hematological malignancies, however, and the appropriate initial cell dose of DLI for treatment of 
recurrent non-CML hematological malignancies after HCT remained unsettled. Thus, the primary 
objective of our study was to determine the effect of the initial DLI cell dose on GVHD and OS 
after DLI in patients treated for any hematological malignancies that relapsed after allogeneic HCT. 
DLI contains a variety of cell types, and the response to DLI could be mediated by several 
mechanisms. T lymphocytes have significant effects on both graft-versus-leukemia and GVHD 
because of their longevity after transfusion in vivo and their ability to target minor 
histocompatibility antigens shared between leukemic and normal host tissue as well as antigens 
unique to leukemia cells 24, 25 and 26. Therefore, we focused our analysis on the effect of the 
initial CD3
+
 T cell dose on GVHD and survival after DLI. This retrospective analysis of 225 
patients confirms that adoptive immunotherapy with donor lymphocytes may be an effective 
treatment for patients with hematological malignancies who experience relapse after allogeneic 
HCT, and the results suggest that the initial CD3
+
 cell dose may influence the outcome 
independently of other relevant factors. 
Our multivariate analysis suggests that the risk for developing GVHD after DLI significantly 
increases with CD3
+
 cell dose ≥10 × 107/kg, regardless of diagnosis, pre-DLI acute or chronic 
GVHD, or interval between HCT and DLI. GVHD, a pathological process initiated by the 
activation of donor T cell after adoptive transfer into the allogeneic recipient [27], has been a major 
direct complication after DLI 7, 17, 24, 28, 29, 30, 31, 32, 33 and 34. Earlier reports demonstrated 
that the dose of allogeneic total nucleated cells and lymphocytes infused for DLI is a risk factor of 
GVHD after DLI in patients with relapsed CML 14, 21 and 30. Chalendon et al. showed that >1 × 
10
7
 CD3
+
 cells/kg was correlated with a higher frequency of GVHD after DLI in patients with 
relapsed CML after HCT [21]. In our study, initial DLI CD3
+
 cell dose of ≥10 × 107/kg was 
associated with a 2.4-fold increase in the risk of GVHD after DLI compared with cell doses ≤1.0 × 
10
7
 in patients treated for any hematological malignancy that relapsed or progressed after allogeneic 
HCT after either high-intensity or reduced-intensity conditioning. Initial DLI CD3
+
 cell dose of 
>1.0 × 10
7
 to <10 × 10
7
/kg was not associated with an increased risk for GVHD compared to a 
lower cell dose. 
We then sought to determine the effect of the initial CD3
+
 cell dose on OS after DLI. Earlier studies 
evaluated the effect of DLI mononuclear cells or T cell dose for the treatment of CML 14 and 15. 
Guglielmi et al. demonstrated that for the treatment of relapsed CML, an initial DLI cell dose of 
≤.20 × 108 mononuclear cells/kg was associated with less GVHD and better survival than higher 
mononuclear cell doses [14]. Similar to the findings by Guglielmi et al., we demonstrated better OS 
for patients with relapsed CML who were treated with lower initial DLI CD3
+
 cell dose. Although 
our association did not reach statistical significance, likely because of the small cohort, our and 
earlier results demonstrate that for patients with CML, initial CD3
+
 cell dose of 1 × 10
7
 or lower has 
survival advantage as compared to higher CD3
+
 cell dose. In contrast to the association between 
initial DLI CD3
+
 cell dose and OS in CML, we did not demonstrate such an association for patients 
with AML or MDS. Earlier analyses to evaluate the correlation between cell dose and response rate 
in AML showed that increasing the cell dose beyond 1.5 × 10
8
 T cell/kg did not add to the response 
rate [35]. A study by Choi et al., however, appeared to show a better response rate with a higher 
dose of T cells [36]. In our study, we demonstrated 3-year overall survival of 32%, 40%, and 28% 
for patients with relapsed AML or MDS treated with ≤1 × 107 CD3+ cells/kg, 1.1 to 9.9 × 107 CD3+ 
cells/kg, and ≥10 × 107 CD3+ cells/kg, respectively (P = .99). Although these results do not 
demonstrate correlation between initial DLI CD3
+
 cell dose and OS, they do show that initial DLI 
CD3
+
 cell dose ≥10 × 107/kg does not provide survival benefit. Therefore, considering that an initial 
DLI cell dose of ≥10 × 107 CD3+ cells/kg is associated with an increased risk of GVHD after DLI, 
our results suggest that initial CD3
+
 cell doses ≥10 × 107/kg should be avoided. Although we found 
no statically significant difference between initial cell dose groups and OS, patients in the low-risk 
disease category might achieve better survival with a lower DLI cell dose ( Figure 2A). Our 
evaluation of the relationship between CD3
+
 cell dose and OS for lymphoma, CLL, and MM 
showed an association between the initial DLI CD3
+
 cell dose and OS; however, this association did 
not reach statistical significance ( Supplemental Figure 1B). The number of ALL patients in our 
cohort was too small to derive significant conclusions. 
Relapse or progressive disease was the main cause of death after DLI at all 3 cell dose groups, with 
no statistically significant decrease in the proportion of patients who died because of relapse among 
patients who were treated with higher CD3
+
 cell doses. 
We then evaluated the association between initial DLI cell dose and relapse or disease progression 
after DLI. Our data demonstrate a decreased risk of relapse and/or disease progression with initial 
DLI CD3
+
 dose of >1 × 10
7
 to <10 × 10
7
 but not with higher cell dose. The results were not 
different when CML-CP patients were excluded from the analysis. Similar observations have been 
made previously in ALL patients treated with DLI [35]. Although no conclusive statement can be 
made because of the small numbers, the lower response rates with higher CD3
+
 cell dose could 
reflect higher numbers of infused T regulatory cells, which might dampen the graft-versus-tumor 
effect. 
This study has several limitations. The data were mostly collected retrospectively, the patient 
population is heterogeneous, patients were treated according to a variety of protocols with different 
treatment strategies, and methods and timing of follow-up were not standardized. Additionally, 
better supportive care has improved the survival of patients who were treated in more recent years 
compared with patients who were treated earlier. Despite those limitations, we believe that this 
study gives a reliable estimate of the effect of initial CD3
+
 cell dose on GVHD and survival after 
DLI for treatment of relapsed hematological malignancies after HCT. 
Our results demonstrate that an initial DLI CD3
+
 cell dose per kilogram ≥10 × 107 is associated 
with increased risks of GVHD after DLI, without improving survival. These findings are clinically 
relevant, because they support a recommendation to infuse less than 10 × 10
7
 CD3
+
 cell/kg as the 
initial cell dose of DLI for treatment of recurrent hematological malignancy, including non-CML 
after allogeneic HCT. 
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